Eisai US

Eisai Inc. is the U.S. subsidiary of Tokyo-based Eisai Co., Ltd., specializing in the development and marketing of innovative therapies in neurology and oncology. Established in 1987, the company is headquartered in Woodcliff Lake, New Jersey, with additional facilities in Massachusetts, Pennsylvania, Maryland, North Carolina, and Ridgefield. Eisai is committed to addressing unmet patient needs through its human health care (hhc) philosophy, which emphasizes ethical practices and innovation. The company has made significant contributions to the pharmaceutical industry, particularly in neurology and oncology. Notable achievements include the launch of Aricept, a leading treatment for Alzheimer's disease, and the development of therapies for epilepsy and cancer. Eisai also collaborates with organizations like Biogen to advance next-generation Alzheimer’s therapies. With a strong focus on research and development, Eisai continues to expand its impact in the healthcare sector, aiming to improve patient outcomes through its innovative solutions.